Form 4: Karyopharm Officer Sells Shares for Tax Liability

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, sold 362 shares of common stock at a weighted average price of $6.296 to cover tax liabilities from PSU vesting.

Summary

• Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported a sale of common stock.
• The transaction involved the disposition of 362 shares of common stock on October 1, 2025.
• The shares were sold at a weighted average price of $6.296 per share, with individual sales ranging from $6.19 to $6.30.
• This sale was non-discretionary, executed pursuant to a Rule 10b5-1 plan adopted on May 27, 2021.
• The purpose of the sale was to satisfy withholding tax liability incurred upon the vesting of Performance Share Units (PSUs).
• Following the transaction, Kristin Abate beneficially owns 10,046 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale by an insider to cover tax liabilities associated with PSU vesting, rather than a discretionary investment decision.

Positives

• The vesting of Performance Share Units (PSUs) implies the achievement of performance targets, which is generally a positive indicator of the company's operational success.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021.
• The sale represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs.
• The sale does not represent a discretionary trade by the reporting person.

Industry Context

This specific insider transaction is a routine, non-discretionary event related to executive compensation and tax obligations, and does not inherently reflect broader industry trends or competitive positioning for Karyopharm Therapeutics Inc.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a small, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The sale of shares by the Chief Accounting Officer is a non-discretionary transaction executed under a Rule 10b5-1 plan to cover tax obligations from PSU vesting. This type of insider sale is routine and does not reflect a change in the company's fundamentals or management's outlook, thus it does not warrant a change in investment recommendation based solely on this filing. Investors should hold their position and consider broader company performance and market conditions.

Keywords

Karyopharm Therapeutics, KPTI, Kristin Abate, Insider Transaction, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan, Tax Liability